ReviewFrontiers in psychiatry2019
Schizophrenia, Not a Psychotic Disorder: Bleuler Revisited.
Review in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Mapping Psychosocial Interventions for Psychosis and Schizophrenia Across Gulf Countries: A Scoping and Narrative Review.Journal of clinical medicine · 2026Review
- Commentary: towards a name change of schizophrenia: positive and negative symptoms disorder (PND).European archives of psychiatry and clinical neuroscience · 2026Article
- Peripheral BDNF Levels in Individuals at Ultra-High Risk for Psychosis: A Systematic Review.Brain sciences · 2025Review
- Autistic Traits in Schizophrenia: Immune Mechanisms and Inflammatory Biomarkers.International journal of molecular sciences · 2025Review
- Psychedelics and schizophrenia: a double-edged sword.Molecular psychiatry · 2025Review
- The Evolution of Symbolic Thought: At the Intersection of Schizophrenia Psychopathology, Ethnoarchaeology, and Neuroscience.Culture, medicine and psychiatry · 2024Article
- The relationship between obsessive-compulsive symptoms and real-life functioning in schizophrenia: New insights from the multicenter study of the Italian Network for Research on Psychoses.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- The Importance of Cerebrospinal Fluid Investigation in First-episode Psychosis.The Yale journal of biology and medicine · 2023Review
- Problematic Smartphone Use Mediates the Pathway from Suicidal Ideation to Positive Psychotic Experiences: a Large Cross-Sectional, Population-Based Study.International journal of mental health and addiction · 2023Article
- Inequality and barriers in psychosis prevention: A systematic review on clinical high-risk for psychosis studies from developing countries.Frontiers in psychiatry · 2023Article
- Conversational metrics, psychopathological dimensions and self-disturbances in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2022Article
- Psychosis and fever revisited.Schizophrenia research · 2022Article
- Cognitive and Global Functioning in Patients With First-Episode Psychosis Stratified by Level of Negative Symptoms. A 10-Year Follow-Up Study.Frontiers in psychiatry · 2022Article
- Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.Scientific reports · 2020Article
- mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine.Journal of molecular neuroscience : MN · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current diagnostic criteria delineate schizophrenia as a discrete entity essentially defined by positive symptoms. However, the role of positive symptoms in psychiatry is being questioned. There is compelling evidence that psychotic manifestations are expressed in the population in a continuum of varying degrees of severity, ranging from normality to full-blown psychosis. In most cases, these phenomena do not persist, but they constitute risk factors for psychiatric disorders in general. Psychotic symptoms are also present in most non-psychotic psychiatric diagnoses, being a marker of severity. Research revealed that hallucinations and delusions appear to have distinct, independent biological underpinnings-in the general population, in psychotic, and in non-psychotic disorders as well. On the other hand, negative symptoms were seen to be far more restricted to schizophrenia, have other underlying pathophysiology than positive symptoms, predict outcome and treatment response in schizophrenia, and start before the first psychotic outbreak. The current work discusses the concept of schizophrenia, suggesting that a greater emphasis should be put on cases where psychotic symptoms emerge in a premorbid subtly increasing negative/cognitive symptoms background. In those cases, psychosis would have a different course and outcome while psychosis occurring in the absence of such background deterioration would be more benign-probably having no, or a milder, underlying degenerative process. This reformulation should better drive psychopathological classification, face positive symptoms as epiphenomenon of the schizophrenia process, and dishevel stigma from schizophrenia and from delusions and hallucinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.